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Drug use is associated with low uptake of HIV antiretroviral therapy (ART), an under-stud-
ied step in the HIV care continuum, and insufficient engagement in HIV primary care. 
However, the specific underlying mechanisms by which drug use impedes these HIV 
health outcomes are poorly understood. The present qualitative study addresses this 
gap in the literature, focusing on African-American/Black and Hispanic persons living 
with HIV (PLWH) who had delayed, declined, or discontinued ART and who also were 
generally poorly engaged in health care. Participants (N = 37) were purposively sam-
pled from a larger study for maximum variation on HIV indices. They engaged in 1–2 h 
audio-recorded in-depth semi-structured interviews on HIV histories guided by a multi-
level social-cognitive theory. Transcripts were analyzed using a systematic content analy-
sis approach. Consistent with the existing literature, heavy substance use, but not casual 
or social use, impeded ART uptake, mainly by undermining confidence in medication 
management abilities and triggering depression. The confluence of African-American/
Black or Hispanic race/ethnicity, poverty, and drug use was associated with high levels 
of perceived stigma and inferior treatment in health-care settings compared to their 
peers. Furthermore, providers were described as frequently assuming participants were 
selling their medications to buy drugs, which strained provider–patient relationships. 
High levels of medical distrust, common in this population, created fears of ART and of 
negative interactions between street drugs and ART, but participants could not easily 
discuss this concern with health-care providers. Barriers to ART initiation and HIV care 
were embedded in other structural- and social-level challenges, which disproportionately 
affect low-income African-American/Black and Hispanic PLWH (e.g., homelessness, 
violence). Yet, HIV management was cyclical. In collaboration with trusted providers and 
ancillary staff, participants commonly reduced substance use and initiated or reinitiated 
ART. The present study highlights a number of addressable barriers to ART initiation and 
engagement in HIV care for this vulnerable population, as well as gaps in current practice 
and potential junctures for intervention efforts.
Keywords: hiV care continuum, antiretroviral therapy, barriers, qualitative, drug use, african-american, Black, 
hispanic
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inTrODUcTiOn
The tolerability, dosing schedules, and efficacy of antiretroviral 
therapy (ART) for HIV infection have improved substantially in 
recent years, allowing persons living with HIV (PLWH) to live 
longer lives, and experience a higher quality of life, than in the 
earlier phases of the epidemic (1). Yet, in the United States (U.S.), 
there are serious gaps in rates of engagement in HIV care, uptake 
of ART, and clinical status – a series of stages referred to as the 
“HIV care continuum” (2). Specifically, of the 1.2 million PLWH 
in the U.S., an estimated 60% are not well retained in care, more 
than half are not prescribed ART, and only 25% have undetectable 
viral loads, the ultimate goal of HIV care, with equally poor rates 
of engagement found among the population of men who have sex 
with men (MSM), who comprise approximately half of all PLWH, 
and other subgroups of PLWH (3). However, African-Americans/
Blacks and Hispanics have lower rates of engagement along the 
HIV care continuum compared to Whites, and in response, the 
Centers for Disease Control and Prevention (CDC) has called for 
efforts to reduce these racial/ethnic disparities (4).
Overall, rates of engagement in HIV care, ART initiation, and 
adherence to ART are less than optimal for persons who use illicit 
drugs or use drugs non-medically and non-users (5, 6). However, 
those who use illicit drugs have higher rates of morbidity and 
mortality compared with their HIV-infected peers who do not 
use drugs (7–9). Moreover, at the individual level, substance use 
problems are associated with decreased access to health care, 
less frequent engagement in HIV primary care, and reduced 
likelihood of being prescribed ART (5, 7–9). Indeed, while the 
literature documenting the associations among alcohol and drug 
use and poor engagement along the HIV care continuum is sub-
stantial (5), and there is a consensus that HIV and substance use 
are twin epidemics (10, 11), the mechanisms that underlie these 
associations remain poorly understood. Past research has found 
that drug use is commonly used as a coping strategy when HIV 
is first diagnosed (12) and can impede engagement in care – a 
critical early stage of the HIV care continuum. Furthermore, 
qualitative research has found that PLWH who internalize stigma 
related to both HIV and substance use are at grave risk for depres-
sion (13), a known barrier to good HIV outcomes. Wilson and 
colleagues reviewed the qualitative research literature pertaining 
to African-American/Black MSM. The review highlighted the 
importance of layered stigma and understanding health behavior, 
including substance use, in context, as well as evidence of resil-
ience in this heterogeneous population (14). The present study 
extends this emerging literature using a multilevel level theory 
to potentially uncover and explore mechanisms and processes by 
which substance use interferes with engagement along the HIV 
care continuum, at the individual-, social-, and structural-levels 
of influence, and how barriers can be overcome, from the per-
spectives of an under-studied population at high-risk for poor 
outcomes: low-income African-American/Black and Hispanic 
PLWH who use/have used drugs, and who have delayed, declined, 
or discontinued ART, including sexual minorities.
We explore how substance use impedes engagement in the 
HIV care continuum through a version of the Theory of Triadic 
Influence (15). The Theory of Triadic Influence is a multilevel 
social-cognitive theory focused on three “streams of influence” 
that act simultaneously to affect health behaviors: the individual 
level (e.g., poor knowledge about ART and HIV care; health beliefs 
such as medical distrust; negative emotions, particularly fear of 
ART; mental health and substance use problems), social level (e.g., 
unfavorable peer norms that impede HIV care and ART, HIV, and 
other stigmas, relations with providers), and structural level of 
influence (e.g., aspects of health-care settings including their loca-
tion, and the ability to access ancillary substance use treatment and 
mental health care). Thus, the Theory of Triadic Influence is useful 
in three respects: first, it guides the selection of domains to explore; 
it draws attention away from a sole focus on individual-level barri-
ers, which are perhaps the most visible, but not necessarily the most 
potent or important; and as a social-cognitive theory, it highlights 
the interplay of the multilevel factors that influence behavior.
For African-American/Black and Hispanic communities 
facing multiple and competing challenges to their health and 
well-being, which stem in large measure from disproportionately 
high rates of poverty, ART initiation and engagement in HIV 
care are especially complex processes. Moreover, these barriers 
to ART and HIV care are grounded in a historical and cultural 
context that includes past maltreatment of populations of color 
in medical research, with the Tuskegee Syphilis Study serving as 
the most notorious example of such abuses, which resonate with 
present-day exclusion, structural inequality, and discrimination 
(16, 17). Thus, this historical/cultural context may serve a filter 
through which HIV care and ART, including the side effects of 
ART, are experienced.
Importantly, the literature on the HIV care continuum focuses 
heavily on whether PLWH are prescribed ART, and rates of viral 
suppression, but there is almost no attention to the intermediate 
stage of individuals electing to initiate ART (18, 19). The present 
study addresses that gap in the literature. We also wish to note 
that the problems of poor engagement along the HIV care con-
tinuum are related. For example, PLWH who have declined ART 
also tend to avoid HIV care, because they do not wish to discuss 
or fear being pressured to take ART, or because they do not see 
the need for HIV care if not on ART (20–22); and those not well 
engaged in HIV care rarely gain access to ART (23). The present 
study attends to ART initiation and engagement in HIV care as 
two separate but related stages in the HIV care continuum.
aims
The aims of the present study were to examine the experiences 
of an at-risk population: African-American/Black and Hispanic 
PLWH who have delayed, declined, or discontinued ART, many of 
whom also insufficiently engaged in HIV primary care. The study 
explores how substance use serves as a barrier to engagement 
along the HIV care continuum through its influences on factors, 
such as access to services, social norms and stigmas, attitudes 
toward and emotions regarding ART and HIV care, and personal 
decisions. The qualitative research approach is appropriate for 
examination of multifaceted, multilevel phenomena such as these 
(12). We hypothesized that the individual perspectives and lived 
experiences of African-American/Black and Hispanic PLWH 
would reveal both the complex social realities that undermine 
their uptake of ART and engagement in HIV care, the meaning 
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of ART and HIV care, and illustrate the diverse ways they have 
navigated these challenges, with varying degrees of success. Thus, 
qualitative studies of this kind are crucial to address the indi-
vidual, social, and structural contexts that either limit or promote 
African-American/Black and Hispanic PLWH’s access to, and use 
of, life-saving care and treatment.
MaTerials anD MeThODs
recruitment
Participants were adult African-American/Black and Hispanic 
PLWH (N = 37) recruited through peer-to-peer referral and in 
hospital-based HIV clinics who were medically eligible for (based 
on national guidelines at the time) but not taking ART, as part 
of a larger intervention development study on increasing ART 
initiation in this group. Participants were purposively sampled 
from a larger sample of 95 PLWH approximately 4–6 months after 
enrolling into the main study. The sub-cohort of 37 PLWH was 
selected for maximum variation with respect to past experiences 
with ART and length of time living with HIV. Almost all par-
ticipants in the larger study reported past substance use (>85%) 
and/or substance use problems, and about half reported recent 
substance use, largely non-injection drug use. Thus, we did not 
sample participants for this qualitative sub-study on substance 
use criteria, and operated under the assumption that, given the 
prevalence of substance use in the lives of PLWH, both past and 
present substance users and non-users would have perspectives 
on how substance use may interfere with HIV care and ART 
initiation, continuation, and adherence. The larger study, its 
recruitment methods, and characteristics of the larger sample 
are described elsewhere (24). Procedures were approved by the 
Institutional Review Boards at New York University and two 
collaborating hospital sites.
The local context
New York City (NYC) has a large and mature HIV epidemic, 
with approximately 115,000 PLWH, more than 75% of whom 
are African-American/Black and Hispanic (25). Overall, NYC 
has achieved higher rates of engagement along the HIV care 
continuum than among PLWH nationally [e.g., 41% in NYC 
are virally suppressed compared to 25% nationally (26, 27)]. 
The city hosts a large network of HIV care facilities and support 
services, including Designated AIDS Centers and AIDS service 
organizations, and some PLWH receive services in local general 
community-based organizations and from private facilities (28). 
Furthermore, all patients in NYC have access to ART at low or 
no cost (29). Nonetheless, NYC evidences serious gaps along 
the HIV care continuum, and many PLWH are diagnosed late 
in the course of their HIV disease (30). Racial/ethnic disparities 
in engagement in care, ART initiation, and viral suppression are 
similar to national patterns, where African-American/Black and 
Hispanic PLWH show the lowest rates of engagement along the 
continuum (31). Moreover, HIV-related death rates are concen-
trated in the highest-poverty neighborhoods (25). Last, quality of 
HIV care varies within care settings [for example, where opioid 
users receive lower quality care than non-users (32) and across 
settings (33)].
Procedures
Data collection took place in 2012–2013. Trained, experienced 
research staff conducted in-depth semi-structured interviews 
until data saturation was reached on core constructs (34), as 
determined by a senior qualitative researcher, who reviewed 
transcripts and queried interviewers during data collection. 
Participants gave signed informed consent before engaging in 
study activities. Interviews were audio-recorded and profession-
ally transcribed verbatim for analysis. Interviews were conducted 
in-person in a confidential location, and each lasted 60–90 min. 
The interview questions followed a guide with core questions and 
prompts that were grounded in the domains of Theory of Triadic 
Influence, covering specific topics relating to (a) the history of 
participants’ personal decisions about ART initiation and con-
tinuation or decline/discontinuation, (b) past experiences with 
ART (where appropriate), (c) perspectives on factors that impede 
or facilitate access to ART, probing for individual, social, and 
structural levels of influence, (d) attitudes toward, and experi-
ences with, HIV primary care, and (e) emergent themes. The role 
of substance use was explored in each of these topic areas.
Data analysis
A systematic content analysis approach was used in phases to 
identify processes and mechanisms of action in the interview tran-
scripts (35, 36). Data were analyzed in the Dedoose platform. First, 
the research team developed a set of preliminary descriptive codes 
based on an initial review of the transcripts and the domains of 
the theoretical model (e.g., emotional barriers, relevance of race/
ethnicity, social class, sexual minority status, and/or gender, rela-
tionships with providers, peer norms). Then, a trained qualitative 
analyst coded each interview transcript using these codes, refining 
and creating additional codes when necessary. We conducted a 
reliability check of the coding in which 25% of the interview tran-
scripts were independently coded by a second qualitative analyst 
to establish high inter-coder reliability and further refine the exist-
ing set of codes (35). Discrepancies in coding were resolved by 
consensus. We used the Memo and Code Cooccurrence functions 
within Dedoose to support analysis of relationships between codes 
and develop larger themes. The two qualitative analysts together 
then identified areas of congruence and discrepancy with respect 
to the broader themes. Finally, excerpts were selected to illustrate 
the main findings and to expand upon the selected themes.
resUlTs
Participant characteristics
Participants ranged in age from 26 to 64 years (M = 48.7 years, 
SD = 9.37 years), as shown in Table 1. The majority (59.46%) 
was male, and among the male participants, 59.10% identified 
as gay, bisexual, or non-heterosexual. Most (78.38%) were 
African-American/Black and 21.62% were Hispanic. Nearly, all 
(97.3%) were from lower socioeconomic status backgrounds. 
On average, participants had lived with HIV for 13.88  years 
(SD = 8.11 years). Approximately half (54.05%) had taken ART 
at least once in the past, and on average, had initiated ART 
on 5.17 different occasions (SD =  5.44 times) prior to study 
enrollment. None were on ART at the time they enrolled in 
TaBle 1 | Description of the sample (N = 37).
Mean (sD) or %
Age (years) 48.7 (9.37)
Male sex 59.46
If male, identifies as gay, bisexual, or non-heterosexual 59.10
African-American/Black, not Hispanic 78.38
Hispanic/Hispanic 21.62
Low socioeconomic status 97.3
health indicators
Years since HIV diagnosis 13.88 (8.11)
Ever taken ART in the past 54.05
Number of times started/stopped ART 5.17 (5.44)
Health self-rating “good” or better 72.97
Had an established HIV care provider over the past year 
(MRF)
83.78
Receives care in hospital-based HIV clinic 77.78
Average CD4 in the year before baseline (MRF) 291.87 (144.15)
Average log10 viral load in the year before baseline (MRF) 3.08 (1.36)
Health-care provider recommended ART (lifetime) 100
Depression screener at a clinically significant level (CES-D8) 50.00
substance use
Smoked cigarettes daily past 6 months 67.57
Any drug use past 6 months 54.05
Daily drug use past 6 months 29.73
Alcohol use 4+ times a week past 6 months 10.81
Substance use treatment – past 6 months 30.56
Ever injected drugs (lifetime) 40.54
Injected drugs in the past 6 months 2.7
Enrolled in methadone maintenance treatment program 
(MMTP) in the past 6 months
8.11
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the study. Most (72.97%) rated their health as “good” or bet-
ter, and the majority (83.78%) had an established health-care 
provider in the past year, mainly at a hospital-based HIV clinic 
(77.78%). HIV health indicators highlighted the need for ART 
based on relatively low CD4 counts, also called T-cells [average 
CD4 =  291.87  cells/mm3 (SD =  144.15  cells/mm3)] and sub-
stantial HIV viral load levels [mean log10 HIV viral load 3.08 
(SD = 1.36)], the primary indices upon which HIV treatment 
decisions are based (37). All reported that a health-care provider 
had recommended ART in the past. Half (50.00%) had symp-
toms of depression at a clinically significant level. Regarding 
substance use, daily tobacco use was common (67.57%), and 
half (54.05%) had used illicit drugs in the past 6 months, such 
as marijuana, cocaine, crack, and heroin. Almost one-third 
(29.73%) used drugs daily in the past 6 months. Approximately 
10% (10.81%) drank alcohol at least four times a week in the past 
6 months, and nearly one-third had participated in substance 
use treatment in the past 6 months (30.56%). A history of injec-
tion drug use was common (40.54%), and 2.7% had injected 
in the recent period. Furthermore, 8.11% were enrolled in a 
methadone maintenance treatment program (MMTP) in the 
past 6 months. Thus, participants were diverse with respect to 
sociodemographic, health, and other background characteris-
tics, in keeping with the sampling approach. A description of 
the psychometric characteristics of structured measures used to 
assess the sample is described elsewhere (24).
Qualitative Findings
Overview
Study findings illuminated relationships among ART uptake, 
HIV care, and substance use for African-American/Black and 
Hispanic PLWH. Overall, decisions regarding and experiences 
with ART were highly complex and emotionally charged, while 
discussions of HIV care attendance patterns were less significant. 
For this reason, the majority of the themes described below 
pertain to ART initiation, while engagement in HIV care is 
either not explicitly discussed or is implied. Participants’ ranges 
of experiences can be broadly organized into the following 
domains. First, heavy substance use, but not necessarily casual or 
social substance use, impedes ART uptake by reducing available 
psychological resources to manage medications, and by trigger-
ing depression, which reduces motivation to maintain health 
behaviors. Yet, management of one’s HIV infection is not a simple 
linear event, and changes to “lifestyle,” followed by initiation or 
reinitiation of ART were common. Second, barriers to ART are 
embedded in the other challenges that PLWH face in their lives, 
which disproportionately affect poor African-American/Black 
and Hispanic PLWH of color (38, 39). Third, some participants 
experienced stigma in HIV medical settings and from other 
institutions, mainly associated with their substance use or past 
substance use. Last, in collaboration with trusted providers and 
ancillary staff, it was common for participants to reduce their 
substance use, access needed psychosocial services, reengage in 
HIV care, and, in some cases, initiate or reinitiate ART. All names 
used below are pseudonyms, and some identifying details have 
been changed.
Mechanisms by Which Heavy Substance Use 
Impedes ART Uptake
Consistent with the literature, participants reported heavy sub-
stance use, particularly crack cocaine use, can indeed interfere with 
ART adherence, and this, in turn, reduced motivation to initiate 
or reinitiate ART. Luzio, a 49-year-old sexual minority man of 
mixed race (White/African-American), who was diagnosed over 
25 years ago, described how substance use can interfere with ART:
(Substance use) does (interfere) at times. Because gen-
erally the crack, it kind of demands full attention when 
I am doing it. Yeah. I am not too functional. I could 
have the medication right there, and while doing crack 
say, oh, I don’t feel like taking them now, keep putting 
them off and time seems to fly when you are doing it, 
that is one major thing. At times I plan to take them at 
noon, but then you have to take them with food, and 
when I am doing the crack I don’t have any appetite 
whatsoever, so it becomes non-conducive to take the 
meds. [112030]
Moreover, participants’ accounts provided further insight 
into how heavy substance use can interfere with HIV medica-
tions. LaTonyia is a 54-year-old heterosexual African-American 
female who was diagnosed with HIV approximately 10 years ago. 
She described how fatigue, depression, and related symptoms, 
which typically followed periods of heavy substance use, left her 
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depleted and unable to manage the demands of medical appoint-
ments and/or adhere to her medication regimen, a pattern echoed 
by other participants:
Well for me, I don’t tend to take my medications 
when I’m using drugs …  ‘Cause I get lazy, or I’ll get 
depressed, I wanna sleep all day, I don’t wanna take my 
medicine … It becomes a major part of a problem when 
you usin’ drugs, for me, takin’ HIV meds. But I just don’t 
care. It’s difficult. [511031]
Furthermore, PLWH, and in particular, African-American/
Black and Hispanic individuals who often have high levels of 
medical distrust, as discussed above, tend to fear ART side effects 
(22), and these fears were heightened for substance-using PLWH. 
As explained by Bill, a 64-year-old heterosexual Latino man who 
was diagnosed over 25 years ago, uncertainty about the potential 
interactions between street drug and ART increased feelings of 
apprehension about beginning or continuing ART. In the fol-
lowing quote, Bill outlines the potential dangers that could result 
from mixing street drugs and ART:
Street drugs has a lot of shit in there that shouldn’t be 
in there, you know what I mean? So I do know that 
some of the medications (give you) nightmares. Some 
medication has some strong effects to them, you know? 
So you know there could be a combination, you know? 
They could be something that’s not going to click, you 
know what I mean? And you don’t know, they could 
put something in the crack that your HIV meds won’t 
attract to, you know what I mean? ‘Cause a lot of shit 
going through street drugs, you know what I mean? 
And they are some HIV medications that don’t react 
properly [512057]
Yet, taking ART is generally expected of PLWH, by their 
families, peers, and providers, and substance use is considered 
unacceptable for PLWH who “should” be on ART. Thus, par-
ticipants reported finding it quite difficult to raise these concerns 
about possible street drug–ART interactions with their health-
care providers. This is complicated by the fact that participants 
commonly feel “pressured” to take ART, and that providers are 
heavily invested in “getting” the patient to take ART, rather than, 
as participants would like, considering “the whole person,” their 
individuality, their life contexts, and the complexities of HIV 
and ART. Jonsie is a 40-year-old heterosexual Latina diagnosed 
approximately 10  years ago, who has never taken ART. Jonsie 
describes these tensions that emerge at the interface of health-
care providers who provide access to life-saving medications and 
who treat a complex health condition in the context of a short 
encounter, and patients who have strong, complicated feelings 
about ART, which cannot necessarily be separated from feelings 
of distrust of medical institutions and medications that are com-
mon in communities of color:
It’s pressure because they tell you if you don’t take your 
medication what can happen to you. But at the same 
time, they don’t tell you when you take your medication 
what’s gonna happen to you too (side effects, toxicities). 
And when you do ask the doctor (about long term side 
effects), the doctor tell you oh, don’t worry about that 
right now. Right now just what you gotta worry about 
now because your – your T-cells 200 – I mean your viral 
is 200,000. This is what you better worry about right 
now. So in my mind I’m like, well, I’m not sick right now 
so then why even bother. [511037]
Jonsie’s narrative highlights a common misconception held by 
PLWH: that ART can be delayed when CD4 counts are low if the 
individual does not feel sick. Yet, these types of misconceptions, 
which often have emotional and cultural roots, are not easily 
addressed in a brief medical encounter by a provider who is 
appropriately focused on treating a complex medical condition. 
Thus, importantly, Jonsie highlights a paradox many PLWH find 
themselves in: ART may improve CD4 counts and reduce viral 
load, but ART can bring serious long-term toxicities. While only 
a serious health crisis may break this deadlock for some PLWH, 
delaying ART until CD4 counts are very low can cause permanent 
damage to the immune system (40).
Although many participants viewed their substance use, par-
ticularly heavy use, as incompatible with ART and engagement 
in HIV care, some were able to adopt strategies to manage their 
substance use behaviors while taking ART with good adher-
ence. Walter, a 32-year-old African-American sexual minority 
man, diagnosed within the past 5  years, shares an earlier time 
when he was reluctant to begin an ART medication regimen. 
He outlines his concern that beginning ART would require him 
to make dramatic lifestyle changes to his recreational drug and 
alcohol use, thus potentially interfering in the clubbing and other 
group activities he takes part in with his peers, activities that are 
meaningful to him as a young Black gay man and that affirm his 
belonging to a community. As Walter explains:
Well, I didn’t want to keep popping pills every 
day … And it’s not a fact of (being a) reminder of me 
being a positive, but it was just the fact that I have to 
make sure to remind myself that once I start (ART) I 
can’t stop … And I have to keep going and keep going 
and keep going. I knew that some things about my 
lifestyle would have to change. [212023]
But at the time of his interview, Walter had recently begun 
taking ART and reported a fairly seamless introduction to inte-
grating medication into his life. In elaborating upon his decision-
making process, Walter describes how he found a way to address 
his concerns with the assistance of his HIV/AIDS providers and 
ancillary staff. The personalized information and other guidance 
he received enabled him to adapt his drug and alcohol use activi-
ties to the demands of his regimen, meeting both his medical and 
social needs:
(T)hat was kind of my main concerns was like, 
okay, how much intake I was going to have to do 
when it came to alcohol, my marijuana intake …  So 
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actually those concerns and questions were actually 
being answered …  I did talk to them about like the 
marijuana intake and my alcohol intake and they were 
very helpful with giving me information and letting 
me know that there are some studies that you can take 
your medication with alcohol. I was just told from my 
doctor yesterday, she said if you are going to drink, 
drink at least a couple hours before you take it. So if 
I’m going out drinking between like the hours of 8 or 9, 
and that’s usually when I take my medication is like 9 or 
10. She said wait about at least three to four hours after 
you’ve had your alcohol and then take your medication. 
[212023]
Thus, Walter recognized that changes to the frequency, timing, 
and/or quantity of substance use would be warranted before initi-
ating ART, but these changes may be realistic when motivation to 
start ART is high, and support services, including harm reduction 
services, are in place.
Barriers to ART Initiation Are Embedded in Other 
Challenges That Low-Income PLWH Face
Rita is a 54-year-old heterosexual Latina diagnosed 15 years ago 
who provided a narrative below that reveals the vulnerabilities, 
uncertainties, and even chaos pervasive in the lives of study 
participants:
I started (ART) in the 80s, I was on AZT and I stopped. 
And then in ‘96 I was on Combivir and something 
else. And then like in 2004 I think I was on some other 
meds … When it [Norvir] first came out it was a liquid 
and my daughter would help me take it … (S)he would 
put the medicine in, and then put on the peanut butter. 
That’s how we got my T-cell count to go up. But then I 
stopped, I started doing drugs again. Then I moved, and 
I was in an abusive relationship, and I had to leave my 
daughter and everybody, and I had to move. And then 
I got on (housing for people living with HIV). And, I 
started taking (HIV) medicine again and then I stopped 
again when I was homeless again. I’ve just been through 
a lot. [511042]
Thus, Rita’s cycles of ART discontinuation and reinitiation fol-
lowed a tortuous path through her periods of homelessness, the 
burdens of drug use, an abusive relationship, and as she describes 
elsewhere in the interview, intense depression and forced separa-
tion from her daughter. Rita’s alternating moves toward and away 
from ART cannot be disconnected from the layers of her life that 
she narrates, and through which she has made sense of her rela-
tionship to her HIV infection, and to HIV care and ART. Indeed, 
the problem of discontinuing ART is entwined with the larger 
context of poverty and its consequences. And yet, by the time of 
her interview, Rita had significantly reduced her drug use, rees-
tablished care with a provider, and reinitiated ART. In fact, Rita 
had been taking a once-a-day ART regimen for about 2 months 
at the time of her interview. When asked what had enabled her to 
reinitiate and adhere well to an ART regimen, Rita described the 
“simple things,” that helped her, such as housing, access to juice, 
and a helpful partner also living with HIV and taking ART:
Yeah, I’m good with it, I’m taking it every day, I don’t 
miss no doses … I don’t like doing it. Trust me, I don’t 
like it. I don’t like having to remember to do it. But it’s 
right in my bed stand and it’s a habit now. I tell my boy-
friend to go get my juice. That’s how I take my medicine, 
he takes his and I take mine … If I tell him to get my 
juice to take my medicine then it reminds him to take 
his medicine. And if his bottle’s there then I know I have 
to take my medicine. It’s the simplest things. [511042]
Rita’s characterization of these supports as “simple” reveals 
how important ordinariness can be to the management of HIV, 
particularly when one has experienced so much chaos in the 
battle to survive homelessness, substance use, intimate partner 
violence, poverty, and HIV simultaneously. Moreover, she high-
lights the critical role of stable housing and social support in ART 
management.
Perceived Stigma Is a Major Barrier to ART and 
HIV Care
Participants reported mixed experiences in health-care settings. 
Both supportive and trusting relationships and negative interac-
tions with providers were commonly reported, as we describe in 
more detail below. In part, this may be due to variability in the 
type and quality of settings that PLWH encounter, as well as to 
the large number of social service and health-care providers they 
encounter in the course of managing a complex health condi-
tion and cooccurring conditions (41). Thus, some settings may 
enact policies or procedures that, perhaps inadvertently, result 
in stigma, and some providers may behave in a manner that 
stigmatizes PLWH, particularly those who use or who have used 
substances (42, 43). It is also possible that PLWH’s position in 
a group vulnerable to “structural violence,” namely, when social 
structures or social institutions harm individual by preventing 
them from meeting their basic needs (44), increases their aware-
ness of, and sensitivity to stigma or perceived stigma (45). In 
particular, participants described ways in which their past or 
current substance use, or the perception among providers that 
they use or have used substances, shaped the quality of and their 
access to HIV care and ART initiation.
In the following quote, Martha, a 49-year-old heterosexual 
Latina diagnosed 15 years ago, discusses the judgment she experi-
ences as coming from one of her health-care providers:
So this provider she really gets on my nerve and she’s a 
physician assistant. I don’t think she know a damn thing 
about HIV meds and she just does whatever …  And 
judge me … Alright, so what? I used drugs and I was a 
prostitute. And I don’t always use a condom … alright, 
alright, and …? [511038]
Martha’s perceptions of stigma and judgment in the health-
care setting are not limited to clinic staff, but extend to other 
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institutions as well. Martha described how her parole require-
ments, as far as she understood them, had left her with little 
choice but to comply with her ART regimen, lest she be sent back 
to prison:
I was on parole … (T)hey did threaten me if we discover 
you’re not taking your medication we’re going to lock 
your ass up. Straight like that, so that was kind of an 
incentive. Because they were going to come and count 
your pills. They never did it, but I don’t know. They 
could have come to the house and said get your pills. 
We counting. Put on a glove. The same way they come 
and do the urine, you know. [511038]
While good adherence to ART has marked health benefits, 
coercing ART adherence may have the counter-productive effect 
of undermining one’s intrinsic motivation to take ART (46). In 
fact, Martha did discontinue taking ART, but is also troubled by 
her declining health. She is overwhelmed by the pressures and 
conflicts she faces from many different directions: the demands 
of her daughter and granddaughter who are currently homeless 
and staying with her in her small apartment; the pressures she 
encounters from her HIV-positive peers, who suggest she is “stu-
pid and could die” if she does not take ART; and a recent break-up 
that has left her emotionally reeling. In addition, the judgment 
she perceives from health-care providers, and the difficulty 
involved in finding a new one, have compounded Martha’s stress 
and led her to become withdrawn and isolated. Consequently, she 
is coping with these multiple stressors by putting off the decision 
about reinitiating ART, but is still gripped with the growing fear 
of contracting an opportunistic infection, a decline in health, or 
even dying during this period before she is ready to restart ART:
So at some point I’ve got to get on track. I don’t want 
to be beating myself in the head with it and then now 
all of a sudden I’m sick, you know. Worrying and being 
stressed. I do that on my own because I’m like to myself, 
damn, I’ve got to take my medication … And I don’t 
have the best provider on the earth. But it’s stressful 
to try to find a provider. For me, it’s stressful for me. 
[511038]
Franklin is a 64-year-old heterosexual African-American man 
diagnosed 20 years ago. Like Martha, Franklin also experiences 
judgment from his health-care provider. In the following excerpt, 
Franklin discusses his frustration with the poorer quality of care 
that he receives, in contrast to a more privileged patient in the 
same setting:
I got pissed behind that one time because  –  at that 
particular time I was using (drugs), okay. (The doctor) 
knew I was using because I was coming up with the 
positive urines … And this guy walked in all nice and 
clean and – and I seen the doctor come out and (he) 
said, excuse me Franklin, I just wanna speak to this 
gentleman for a second. I said yeah, but – what do you 
mean? I gotta leave too. He say, listen, just give me five 
minutes. You know he took the guy in the office. They 
was in there for almost an hour. And then he comes 
back out and apologize to me, I’m sorry it took so long. 
Why, because the guy had a suit and tie on. This was the 
impression he gave me … And he could look at him and 
tell that he must have had a good job but he’s HIV, but 
he had priority over me because the class of person that 
he was in. [112014]
Thus, Franklin expresses his concern to his doctor (“I gotta 
leave too”), only to be met with the promise of, “just five minutes.” 
The doctor’s subsequent actions illustrate what his reply actually 
translated to, the simple but powerful directive: “wait.” Unlike 
the freedom to speak and welcome which the doctor extended 
to the well-dressed, unscheduled patient, Franklin felt little 
choice but to wait for his own appointment and grapple with the 
implications of being a poor, African-American, HIV-positive, 
and drug-using man whose time is treated as less valuable than 
that of his wealthier peers – a hierarchy created and reinforced, 
in many cases, by the larger society.
Whereas Franklin’s experience represents the differential care 
that substance-using poor African-American/Black and Hispanic 
PLWH of color may encounter through a particular incident, 
Chryssy’s narrative speaks to the larger negative perceptions 
she believes are held by some providers toward their patients, 
and by the larger society, a phenomenon that she, a 49-year-old 
heterosexual Latina diagnosed 5 years ago, sees as a mundane, 
even commonplace, aspect of her and her HIV-positive peers’ 
experiences.
Most of everybody that I know has HIV, because I live 
in an HIV community and like to describe it as a quag-
mire. You get cooled down into this – the lowest form of 
life because we all live below the poverty level, we don’t 
have jobs, and it is not because we are not qualified to 
have jobs, but because it is not practical to have jobs 
(because you will lose your public assistance benefits). 
And the outside world, the mental health providers, 
and the other people who provide services to you often 
mistreat you. [512038]
Chryssy also discusses how she was greatly affected by the 
death of her life partner two decades earlier, due in part to kidney 
failure following experimental treatment for Cytomegalovirus 
(CMV). The feelings of grief and loss continue to affect Chryssy 
daily, and she had a period of intense drug use immediately fol-
lowing her partner’s death. Furthermore, she faces suspicion from 
providers that she had sold her ART medications, presumably to 
buy drugs:
Oh, okay, let me ask you this question, blah blah blah. 
Well did you sell your medication? Automatically that 
is the first question, did you sell them? No I didn’t. I am 
only going to tell them this and this and that … I say 
I am not taking medication, but the conclusion that 
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they will jump to is that, oh you just want to sell your 
medication, you know? People are very complicated. 
Like, people’s lives are very complicated and we cannot 
all be put into a particular box as to why we do what we 
do. [512038]
Participants describe that in NYC, as in other major urban 
areas, there exists a thriving underground prescription drug 
economy for the resale of ART, mainly to pharmacies, often called 
“drug diversion” (47). In fact, some participants had sold their 
ART prescriptions in exchange for cash, almost always to corrupt 
pharmacies, whereas many others had heard about or were famil-
iar with these practices. In the following quote, Ari, a 64-year-old 
heterosexual African-American male, diagnosed over 20  years 
ago but who has not yet taken ART, shares his observations of his 
HIV-positive peers who sell their medications to pharmacists for 
“easy money,” motivated by their desire or need for illicit drugs, 
and, he believes, with little regard for their own health:
You know everyone that I know that sells their medica-
tions, they know the consequences of not taking that 
medication …. And if you have a history of using drugs 
and if you actively using now you’re definitely gonna 
through the measures of trying to get everything – do 
everything that’s possibly to get money. Medication is 
the … easy way of getting money, okay, and they know 
the consequences of not taking medication. They know 
their T-cells are dropping, their immune system is 
weak and they don’t care. They’re willing to sacrifice 
that. [112014]
However, not all participants would agree with Ari’s point that 
the HIV-positive person who sells their medication in exchange 
for cash (and as some reported, sundries such as toothpaste and 
deodorant) is fully cognizant of and accepts the known risks of 
not taking their medications. While undoubtedly some are, oth-
ers may not fully understand its effects, nor would they have the 
opportunity to discuss these concerns with their prescribing doc-
tors, as to do so would threaten their relationships with providers 
and prevent their involvement with this informal cash economy. 
Luli is a 50-year-old Latina sexual minority diagnosed 8 years ago. 
According to Luli, her doctor’s ambivalence as to whether she 
should begin medication or not was evidence that she could man-
age without them, and she does not expect that her decision to sell 
her ART medications will adversely affect her health. Moreover, 
Luli views that her decision to delay ART had another significant 
benefit, a financial one:
And I know I think I’m killing myself but until the doc-
tor say I’m killing myself, I’m not killing myself. It’s like 
the devil on this side saying do it, do it, do it. Doctor said 
I should take it but then she said I don’t need it. That’s 
when I said, well, if I don’t need it I’m not going to take 
it. But then there’s money in it … It was worth it for me. 
I’m going to be honest with you. He [the pharmacist] 
take the med, so I get $200. My numbers is not being 
damaged further and then it’s not like I’m taking the 
money and just fucking it up. For me to get the extra 
money, because we set on a set budget. And sometimes 
when you have $330 (a month), an extra $200, I could 
buy some nice stuff. [511033]
Implicit in Ari and Luli’s narratives, and underlying the need 
or desire to divert ART for cash, are the constraints of poverty and 
difficulties surviving on public assistance, and, perhaps, unmet 
need for harm reduction and other acceptable substance use 
treatment services. As Luli suggests, funds from drug diversion 
nearly double her monthly income – and this may be difficult if 
not impossible to resist when offered by the pharmacy, including 
in geographical locations with a high cost of living but relatively 
modest monthly government entitlements. As noted above, the 
problem of ART delay or discontinuation cannot be separated 
from the larger context of poverty.
Positive Relationships with Health-Care Providers 
Facilitate ART Uptake and HIV Care
For the majority of participants, the ability to communicate 
openly and honestly with health-care providers played a critical 
role in determining whether they were willing to continue to seek 
HIV care and to eventually consider initiating or reinitiating ART. 
Individuals reported being substantially more forthcoming with 
their providers when they perceived them as non-judgmental and 
compassionate, and when they felt that providers gave them the 
time and information necessary to come to an independent deci-
sion about ART. Being able to speak openly about substance use 
and how this relates to an individual’s readiness to initiate ART on 
one’s own terms were also repeatedly invoked as positive aspects 
of participants’ HIV care experiences, and in turn as important 
facilitators to continuing to seek HIV care and to consider initiat-
ing ART.
Luzio describes how he recently recommitted to an ART regi-
men, following several years of poor adherence and stopping and 
starting ART. Since the passing of his lover and his drug relapse 
several years prior, Luzio’s goal is not to attain full sobriety as he 
had done in the past, but to manage his drug use in preparation 
to restart his regimen. This process included, as he put it, “telling 
the truth” to his provider regarding his inconsistent use of ART 
and disclosing that he had been selling the medications he had 
been prescribed. Luzio recalls that he had shared similar informa-
tion with other doctors previously, who he said “really gave it to 
him,” to which he responded by disengaging from care. How did 
he know that this disclosure process would be different with his 
current doctor? Luzio explains that these doctors do not judge 
or condemn him, and as he expected, listened to him, gave him 
support, and helped him plan and prepare his reinitiation of ART:
Actually my provider, my primary is on maternity 
leave and before she left I told her I planned on starting 
(ART). She did urge me, she said you need to get off 
those drugs, I mean not preachy like or anything, not 
in a way that I was apprehensive or anything, but get 
off those drugs and get onto your meds. She said, I am 
going to go on maternity leave probably for a couple of 
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months and I hope to see you have begun your meds. 
Which I have, so she has been gone about three weeks 
and I have started like a week after she – but I saw in lieu 
of her, because she is on leave, a doctor I seen before, 
used to see actually, from the same clinic. Yeah. He is 
encouraging too. [112030]
Mental health care is another critical aspect of ART initiation. 
Dewan is a 53-year-old heterosexual African-American man, 
diagnosed within the past 10 years, who was considering initiat-
ing ART, and who did eventually decide to start taking it. He 
discusses the support he received from his therapist to address the 
problems substance use were causing in his life, which included, 
but were not limited to, reinitiating ART:
She was very helpful. She constantly called me at my 
home, at that time I was battling a severe substance 
abuse problem, y’know what I mean? And I would 
actually talk to her about that. And she actually helped 
me get sober. She really did, yeah [name deleted]. Yup, 
mm-hmm … I remember she would call me down for 
a meeting and I would go in there bawling and crying. 
And I could talk to her about anything. There was 
nothing I couldn’t talk to her about. ‘Cause she knew 
that, one thing she did say to me, she said part of getting 
you to take medication, and getting ready to make this 
decision is that you got all this other stuff, y’know, on 
the fire, y’know what I mean, how it’s hard for you to 
really even consider to take this medication. [211009]
Dewan’s therapist facilitated open communication about a 
challenging issue and allowed him to address his substance use 
issues and helped move him forward in his goals to take ART. By 
contrast, Dewan’s experiences with his medical providers were 
markedly different from that with his therapist. Below, Dewan 
discusses how providers assumed that he would never take 
medications, even though he had expressed wanting to do so for 
some time:
First of all, nobody could believe I actually took the 
medicine. And see that’s what bothered me. That God, 
you guys thought that little of me, y’know what I mean, 
your opinions? [voice changes to one of surprise] “Oh 
shit, you actually takin’ it?” Like, what you think? I 
didn’t want to take it? That means, it sounded to me like 
nobody listened. Nobody really listened to “Dewan.” 
Y’know what I mean? And that is kinda hurtful. And 
then you want to know why nobody want to believe in 
the medical system? Yeah like, well. Duh! [211009]
And finally, Benjamin discusses the difference when receiv-
ing care from providers who take a harm reduction-oriented 
approach versus those who do not. In the following passage, 
Benjamin, a 45-year-old sexual minority Latino man diagnosed 
10 years ago, explains how his drug use was identified as prob-
lematic in a care setting that did not meet people “where they 
were at,” compared to the harm reduction program where he 
sought HIV care and was even able to reinitiate an ART regimen. 
Similar to participants who face multiple, chronic, and long-
term challenges – from homelessness to diabetes to hepatitis C 
virus – Benjamin’s engagement with HIV care and adherence to 
ART is greatly affected by his drug use and mental health issues:
Even when I came to New York City, I was doing pretty 
well, but then I just like after a while, like the regimen 
got to be so –  like, the different pills. Three different, 
you know. I was like, let me stop it altogether. Plus, 
you know, I was an addict, you know. Drinking. And 
I picked up the drug called crack cocaine …  So, that 
right there, you know, it’s not really a good – But they 
even say, even if you are drugging still keep taking your 
medications … I was off my medication and I wanted 
to go back to, you know – and I had left [AIDS Service 
Organization]. [AIDS Service Organization] was my 
actual doctor. I left there. I went to [large hospital] and 
I didn’t really like the providers that were there ‘cause 
they didn’t really use the (harm reduction) model as 
to – meeting you where you’re at. And then they said, 
well, you know, we found cocaine in your system. I’m 
like okay, so, okay, but, you know, I’m actually using. But 
then I went back to [AIDS Service Organization], and 
I was able to disclose a lot of those things about mental 
health issues. The nurse practitioners, they were able to 
understand that mental health does play a part in people 
not taking their HIV medication. It also plays a part in 
if you’re using. You’re not concerned about taking your 
medication. So I was able to have part in my care where 
she put me on Stribild (a one-pill, once-a-day complete 
ART regimen). [512047]
These seemingly disparate experiences regarding ART initia-
tion and discontinuation share a unifying principle: participants 
were not strictly bound by one or the other outcome (that is, either 
engaged in care and taking ART or not engaged and not taking 
ART), but frequently moved back and forth between the two, thus 
providing many possibilities for intervention along the way.
DiscUssiOn
Past research has documented the associations among substance 
use and poor engagement along the HIV care continuum and 
with adverse HIV health outcomes. In particular, crack cocaine 
use, heroin use, and poly-substance use are the strongest pre-
dictors of ART non-adherence compared to other substances 
(48–51). However, little research has examined the relationship 
of substance use to ART initiation, an important but under-
studied stage in the HIV care continuum, nor has it captured 
the mechanisms by which substance use impedes ART initiation 
and engagement in HIV care from the perspectives of PLWH 
themselves. Our qualitative study addresses these gaps in the 
literature by providing a rich description of these phenomena 
among African-American/Black and Hispanic PLWH who have 
delayed, declined, or discontinued ART, many of whom were also 
not well engaged in HIV care. The Theory of Triadic Influence 
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proved useful in drawing attention to social- and structural-level 
barriers to ART initiation and HIV care, and how they manifest 
at the individual level, in addition to the individual-level barriers 
that are most prominent in the literature. Importantly, this study 
highlights how the problems of ART delay or discontinuation 
and poor engagement in HIV care cannot be separated from 
the larger context of poverty and structural violence against/
structural racism toward African-American/Black and Hispanic 
PLWH (17, 44, 52–54). Indeed, substance use problems generally 
occurred within relations of marginalization grounded in pov-
erty, such as insecure housing, intimate partner violence, lack of 
employment opportunities, and other forms of deprivation, all of 
which complicate health-care decisions and access. Furthermore, 
results highlighted the complex social position of most partici-
pants, namely, HIV-infected, poor, African-American/Black or 
Hispanic, female (in some cases), sexual minority (in some cases), 
formerly incarcerated (for some), and drug using. This confluence 
of multiple stigmatized identities shaped participants’ experiences 
in HIV care and approaches to ART. These findings are consist-
ent with an intersectionality lens, a health disparities framework 
that posits that social categories, such as “substance user” and 
“person of color,” are much more than the sum of their parts, but 
instead are mutually constitutive and interdependent (55, 56), as 
these study results illustrate. Yet, in the context of a confluence 
of stigmatized identities in this population, results highlighted 
the utility of placing substance use in the foreground, because, 
as the present study highlights, substance use is a primary, visible 
impediment to ART initiation and HIV care for this group.
Thus, the present study sheds light on the various ways substance 
use interferes with ART uptake. We found that heavy substance 
use served as a barrier to ART initiation and HIV care by shifting 
priorities away from health behavior, reducing confidence in one’s 
medication management skills, perhaps rightly so in some cases, 
and triggering depression, which reduced motivation to initiate 
ART. Furthermore, medical distrust appears to be an important 
contributing factor. Participants, already wary of ART and ART 
side effects (57), were in particular fearful of potential interactions 
between street drugs and ART that might lead to adverse side 
effects. However, they did not feel they could discuss this concern 
with providers. Furthermore, providers’ assumptions about drug 
diversion were an additional set of thorny issues adversely affect-
ing patient–provider relationships, and impeding ART uptake, 
from the perspectives of PLWH. Thus, the patient–provider 
interface is an important avenue for intervention. Although stud-
ies of patient–provider communication are numerous in the HIV 
clinic context (32, 58), little is known about strategies to elicit 
and ameliorate the patients’ fears and providers’ assumptions, 
some accurate, some false, associated with PLWH’s substance use. 
In fact, Kreps argues that racial disparities in health outcomes 
are related to communication problems within the health-care 
system, which lead to unequal access to health information and 
inadequate participation in health-care decision-making (59).
The non-linear Path of Managing hiV 
infection
Participants’ relationship to ART initiation and their efforts to 
engage in care rarely followed a linear, predictable path, but rather 
one marked by varying degrees of ambivalence and uncertainty. 
Current treatment guidelines recommend that patients initiate 
ART as a long-term commitment and avoid unscheduled inter-
ruptions that lead to drug resistance and increase the chance of 
treatment failure (37). However, this goal does not seamlessly 
align with the clinical complexities, competing demands, and 
pressing social realities, including substance use, faced by 
African-American/Black and Hispanic PLWH. In fact, in a quali-
tative study of people who had recently been diagnosed with HIV 
at an urban public hospital, definitions of what it meant to engage 
in care by PLWH did not readily match provider definitions; for 
some participants, their contact with medical and ancillary staff 
was their engagement in care, despite that they might not have 
been considered active clinic patients and were thus deemed to be 
disengaged from care (60). This suggests the need to adapt path-
ways to care that privilege patient’s experiences and the meanings 
they attach to these processes. Similarly, Muessig and colleagues 
note that adherence interventions need to better convey adher-
ence as a continuous, changing process, rather than a fixed state 
(57), and as we found in the present study, ART initiation deci-
sions and behavior, the precursor to adherence, follow this same, 
changing course.
The role of Multiple stigmas
From the perspectives of PLWH, both their actual and perceived 
substance use patterns were associated with stigma directed at 
them from some HIV health-care providers and in other settings 
they encountered. Furthermore, these experiences of stigma 
were common impediments to engagement in HIV care and 
uptake of ART. Indeed, it is well documented that both HIV- and 
substance use-related stigma are composed of the dimensions of 
stereotyping, prejudice, and discrimination, are directed toward, 
and experienced and internalized by PLWH, and this, in turn, can 
impede engagement in HIV care (13, 43, 61–63). But, participants’ 
narratives also illustrated that the judgmental stance they experi-
ence toward their perceived substance use cannot be disentangled 
from their socioeconomic status, race/ethnicity, involvement 
in transactional sex, sexual minority status, and/or histories of 
incarceration. The Theory of Triadic Influence proved, again, to 
be well suited to our qualitative investigation. While any one of 
these factors alone –  individual, social, and structural – would 
reveal important insights about the phenomena under study, it 
was by unpacking barriers at multiple levels of influence that we 
begin to observe their complex dynamics.
Thus, as we have noted, the present study highlights how the 
problems of low uptake of ART and engagement in HIV care 
emerge from poverty and structural violence (17, 53). While this 
study raises the question of whether HIV care providers stigma-
tize PLWH who use substances, it also raises questions regarding 
what larger structural or societal factors foster those interactions. 
Indeed, understanding stigma perceived by PLWH to originate 
from health-care providers and settings cannot be separated from 
the larger context, which include an overburdened health-care 
system where providers may be overwhelmed and frustrated 
by the system in which they operate, particularly as they treat 
patients with multiple comorbidities and psychosocial needs (64). 
For example, a recent survey of over 700 HIV clinicians revealed 
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their decisions to delay prescribing ART among substance users 
even when medically warranted, primarily because of their con-
cerns that patients would lack the stability needed to adhere to 
the demanding regimen (65). Indeed, in some cases, this concern 
may be warranted, as participants in this study discussed. On 
the other hand, in our own past research with HIV primary care 
providers in NYC, we found that HIV care providers reported 
considerable challenges balancing a non-judgmental attitude 
about substance use and promoting better health among their 
patients, stemming mainly from a lack of training regarding and 
understanding of substance use and its treatment (66). Indeed, 
HIV care providers expressed frustration about their inability to 
address substance use concerns as effectively as they did those 
associated with HIV. Furthermore, as infectious disease physi-
cians are often the primary providers of HIV care, some reported 
they had little interest in addressing substance use concerns. This 
mismatch between providers’ skills and interests and participants’ 
needs may be experienced as stigma. Thus, providing enhanced 
substance abuse training to HIV care providers in HIV clinics, as 
well as ancillary and complementary services and interventions 
in HIV clinics, has potential to reduce experiences of stigma and 
thereby improve patients’ engagement in care and treatment 
outcomes, and possibly improve health-care workers’ experi-
ences of providing HIV care. Our analyses support findings in 
the literature that show that health-care providers may indeed 
benefit from further training in substance use and mental health 
treatment issues (67). Indeed, settings that have integrated sub-
stance use treatment, including harm reduction approaches along 
with HIV medical care, may be especially well suited to provide 
comprehensive HIV care for PLWH who use drugs (68).
Managing substance Use in Order to 
initiate arT
Study findings also demonstrate that substance use did not uni-
versally pose a barrier to participants’ initiation of ART. Several 
participants described how they were able to integrate their sub-
stance use – whether through harm reduction, abstinence-based 
treatment, or behavior modification – into their engagement with 
HIV care, including ART initiation. Access to non-judgmental 
support through medical and ancillary health providers was a 
primary mechanism by which participants initiated ART and 
engaged in HIV care. Participants highlighted how therapists, 
nurses, case managers, and physicians in some cases were able 
to engage them in a supportive manner over a period of time, 
building trust and communication, a model of care that departs 
from the typically narrow focus on single health interventions to 
treat a health condition. Participants’ discussion of these experi-
ences foregrounds the significance of compassion, care, respect, 
and being treated as a “whole person.” This may be a key, if not 
primary, component of successful ART initiation and adherence, 
as well as general medical care of HIV-infected individuals who 
have many cooccurring medical and psychosocial needs. In fact, 
ancillary service providers may be critical in this respect, given 
the demands for health-care providers to maintain short appoint-
ment times. However, all providers have tremendous power to 
influence their patients’ decisions, as we highlight above.
limitations
One general limitation of this study is that its purposive sampling 
method may limit its generalizability to African-American/Black 
and Hispanic PLWH as a whole. Our qualitative sample was, how-
ever, drawn from a larger study sample, which reflects several key 
demographic features present in the HIV/AIDS epidemic in NYC 
with regards to race, gender, age, socioeconomic status, and years 
since diagnosis. The purposive, rather than random sampling 
method, is fitting with the goals of qualitative research, which 
aims for depth rather than breadth. Despite these limitations, 
this qualitative study offers insights into the needs and challenges 
faced by African-American/Black and Hispanic PLWH who have 
past histories of, or are currently using substances, but who are not 
equally benefiting from the treatment advances that have brought 
significant improvements to PLWH’s quality of life and extended 
its length. Future research will be extended to include the perspec-
tive of providers, and to examine policy and structural barriers to 
good HIV outcomes for this population in greater detail.
implications
The present study highlights a number of addressable barriers to 
ART initiation and engagement in HIV care for this vulnerable 
population of PLWH, as well as gaps in current practice and 
potential junctures for intervention efforts. Indeed, study findings 
suggest the need for interventions at the level of individual PLWH 
(e.g., to reduce barriers and motivate and support readiness to 
initiate ART and concomitant changes to substance use patterns 
when appropriate); health-care providers (e.g., increase skill and 
comfort to assess and manage substance use among PLWH and 
understand stigma and its causes and effects); health-care settings 
(e.g., to supplement the brief health-care encounter with services 
for substance users including those with the harm reduction 
approach); and larger organizational and social structures (e.g., 
stable housing, adequate income support, and the transition out 
of incarceration).
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